Emin KAYA, Mehmet Ali ERKURT, Irfan KUKU, Ahmet SARICI, Ilhami BERBER, Soykan BİÇİM, Mustafa ÖZGÜL

Life saving effect of early use of convalescent plasma in Covid-19 treatment

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, which is detected by the transmission from bat to person in Wuhan Province of China, has shown its effect all over the world in a very short time. There is no treatment method proven effective in Coronavirus disease 2019 (COVID-19) pandemics. The whole world is still working on it. Convalescent Plasma (CP) treatment is a passive antibody treatment that has been shown to be effective during periods of epidemic disease in history. CP treatment is interesting in the treatment of virus infection without vaccine or specific treatment, such as SARSCoV-2, which causes COVID-19. The mechanisms of action of CP include neutralizing the virus by direct binding, initiating virus elimination by complement activation, antibody-dependent cellular cytotoxicity and / or phagocytosis. Neutralizing antibodies are the most important mechanisms of action. The most important point in recovery is the inactivation of the virus and the prevention of viral replication. It was demonstrated for the first time that CP significantly reduced mortality in COVID-19 disease. Our results of CP treatment in COVID-19 patients have been published. We have shown that CP is effective and safe in COVID-19 disease. We aimed to gather CP experiences up to date in COVID-19.

PDF

___

1. Shahani L, Singh S, Khardori NM. Immunotherapy in clinical medicine: historical perspective and current status. Med Clin North Am 2012;96:421-31.
2. Roberts DJ, Miflin G, Estcourt L. Convalescent Plasma for COVID-19: back to the future. Transfus Med 2020;30.
3. O’Malley JJ, Hartman FW. Treatment of influenzal pneumonia with plasma of convalescent patients. JAMA 1919;72:34-7.
4. Korkmaz S, Medeni SS, Demirkan F, et al. The Turkish experience with therapeutic plasma exchange: A national survey. Transfus Apher Sci 2019;58:287-92.
5. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J Heart Lung Transplant 2020;39:405.
6. Yigenoglu TN, Hacibekiroglu T, Berber I, et al. Convalescent plasma therapy in patients with COVID-19. J Clin Apher 2020;35:367-73.
7. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757- 65.
8. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80-90.
9. Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323:1824-36.
10. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci 2020;117:9490-6.
11. Gok S, Bahcecioglu OF, Arisoy S. Current Treatment Approaches for COVID-19’in Adults. J Lit Pharm Sci 2021.
12. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
13. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9.
14. Casadevall A, Pirofski L-A. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545-8.
15. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020;35:e149.
16. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020;158:e9-e13.
17. Erkurt MA, Sarici A, Berber I, et al. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. Transfus Apher Sci 2020;59:102867.
18. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020;324:460-70.
19. Altuntas F, Ata N, Yigenoglu TN, et al. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci 2021;60:102955.
20. Mazhar M, Waseem M. Agammaglobulinemia. StatPearls [Internet]: StatPearls Publishing; 2020.
21. Senefeld J, Klassen SA, Ford SK, et al. Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review. medRxiv. 2020.
22. Jamir I, Lohia P, Pande RK, et al. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg 2020;24:526.
23. London J, Boutboul D, Lacombe K, et al. Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy. J Clin Immunol 2020:1-6.
24. Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19. Blood 2020;136:2290-5.
25. Libster R, Marc GP, Wappner D, et al. Prevention of severe COVID-19 in the elderly by early high-titer plasma. medRxiv. 2020.
26. Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020;190:2290-303.
27. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG. Am J Pathol 2020.
28. ah Yoon H, Bartash R, Gendlina I, et al. Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC. medRxiv 2020.
29. Alsharidah S, Ayed M, Ameen RM, et al. COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study. Int J Infect Dis 2021;103:439-46.
30. Ahmad A, Salsabil M, Oliver T. Mortality rates in matched cohort, pseudo-randomised and randomised trials of convalescent plasma given to COVID-19 patients. medRxiv 2020.
31. Moore JL, Ganapathiraju PV, Kurtz CP, et al. A 63-YearOld Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep 2020;21:e927812.
32. Baang JH, Smith C, Mirabelli C, et al. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis 2021;223:23-27.
33. Luetkens T, Metcalf R, Planelles V, et al. Successful transfer of anti–SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv 2020;4:4864-8.
34. Van Damme KF, Tavernier S, Van Roy N, et al. Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19. Frontiers in immunology 2020;11.
35. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371.
36. Budhiraja S, Dewan A, Aggarwal R, et al. Effectiveness of Convalescent Plasma Therapy in Indian Patients with COVID-19. 2020.
37. Kemp SA, Collier DA, Datir R, et al. Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. medRxiv. 2020.